Relmada Therapeutics (RLMD) Capital Expenditures (2014 - 2019)

Relmada Therapeutics (RLMD) has 6 years of Capital Expenditures data on file, last reported at $84.8 million in Q4 2019.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $84.8 million in Q4 2019; TTM through Dec 2019 was $84.9 million, a N/A change from a year earlier, with the FY2020 full-year figure at $182.1 million, up 114.56% from the prior year.
• Capital Expenditures for Q4 2019 stood at $84.8 million, up from $9800.0 in the prior quarter.
• Over the last five years, Capital Expenditures for RLMD reached as high as $84.8 million in Q4 2019 and fell as low as $1310.0 in Q3 2015.
• Historically, Capital Expenditures has averaged $6.6 million across 5 years, with a median of $9800.0 in 2018.
• Across the five-year window, Capital Expenditures surged 7204.54% in 2015 and plunged 99.49% in 2016, its largest moves.
• Year by year, Capital Expenditures stood at $474795.0 in 2015, then plunged by 99.49% to $2434.0 in 2016, then gained by 6.45% to $2591.0 in 2017, then soared by 278.23% to $9800.0 in 2018, then surged by 865708.14% to $84.8 million in 2019.
• Per Business Quant data, the three most recent Capital Expenditures figures were $84.8 million in Q4 2019, $9800.0 in Q2 2018, and $2591.0 in Q3 2017.